Prednisolone
Evidence Level: L1 | Predicted Indications: 5 | Recommendation: Go
Ringkasan Satu Baris
Prednisolone is a glucocorticoid with anti-inflammatory and immunosuppressive effects. TxGNN predicts it may be effective for lymphosarcoma and orbital diseases, supported by multiple Phase 3 clinical trials and extensive literature, achieving the highest evidence level L1.
Prednisolone is already a standard component of CHOP chemotherapy for lymphoma. The KG predictions align with established clinical practice, confirming high validity of the model.
Gambaran Ringkas
| Item | Content |
|---|---|
| Original Indications | Inflammatory conditions, Allergic disorders, Autoimmune diseases |
| Top Predicted Indications | lymphosarcoma, disease of orbital region, erythema multiforme |
| Best Evidence Level | L1 |
| Malaysia Status | Approved (38 products) |
| NPRA Licenses | 38 |
| Recommendation | Go |
Analisis Petunjuk Diramalkan
1. Lymphosarcoma L1 Go
### Mengapa Ramalan Ini Munasabah
Corticosteroids induce lymphocyte apoptosis through glucocorticoid receptor activation. Prednisolone is a standard component of the **CHOP** (Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone) chemotherapy regimen, which is the gold standard treatment for non-Hodgkin lymphoma.
### Ujian Klinikal
| Trial ID | Phase | Status | Enrollment | Key Finding |
|----------|-------|--------|------------|-------------|
| [NCT03206671](https://clinicaltrials.gov/study/NCT03206671) | Phase 3 | Active | - | B-NHL 2013 Treatment Protocol |
| [NCT03007147](https://clinicaltrials.gov/study/NCT03007147) | Phase 3 | Active | - | Ph+ ALL International Trial |
| [NCT00054236](https://clinicaltrials.gov/study/NCT00054236) | Phase 1 | Completed | - | Umbilical Cord Blood Transplant |
**Trial Summary**: 17 Phase 3 trials (9 completed), 15 Phase 2 trials, 3 Phase 4 trials
### Literatur
| PMID | Year | Type | Key Finding |
|------|------|------|-------------|
| - | - | Clinical Trial | 5 clinical trial publications |
| - | - | Review | 4 review articles |
| - | - | Case Reports | 4 case reports |
2. Disease of Orbital Region L1 Go
### Mengapa Ramalan Ini Munasabah
Anti-inflammatory effects reduce orbital tissue edema and inflammation. Prednisolone is commonly used for **Graves' ophthalmopathy** and **idiopathic orbital inflammatory disease**.
### Ujian Klinikal
| Trial ID | Phase | Status | Enrollment | Key Finding |
|----------|-------|--------|------------|-------------|
| [NCT05049603](https://clinicaltrials.gov/study/NCT05049603) | Phase 3 | Not Yet Recruiting | - | Orbital Disease Treatment |
| [NCT04501367](https://clinicaltrials.gov/study/NCT04501367) | Phase 4 | Unknown | - | DEXTENZA Efficacy Study |
| [NCT00406042](https://clinicaltrials.gov/study/NCT00406042) | NA | Completed | - | Prednisolone in Trabeculoplasty |
**Trial Summary**: 12 Phase 3 trials (5 completed), 11 Phase 4 trials (5 completed)
### Literatur
- 20 PubMed articles including EUGOGO clinical practice guidelines
- 7 case reports on orbital inflammatory disease
- 2 systematic reviews
3. Erythema Multiforme L2 Research Question
### Mengapa Ramalan Ini Munasabah
Immunomodulatory effects control hypersensitivity reactions. Corticosteroids are used in the management of **Stevens-Johnson syndrome** and **toxic epidermal necrolysis** spectrum disorders.
### Ujian Klinikal
**Trial Summary**: 3 Phase 3 trials (2 completed), 7 Phase 2 trials (6 completed)
### Literatur
- 20 PubMed articles
- 14 case reports
- 4 reviews
- 1 meta-analysis (Cochrane systematic review)
4. Rheumatic Heart Disease L2 Research Question
### Mengapa Ramalan Ini Munasabah
Anti-inflammatory action reduces cardiac inflammation during acute rheumatic fever, potentially preventing long-term cardiac damage.
### Ujian Klinikal
| Trial ID | Phase | Status | Key Finding |
|----------|-------|--------|-------------|
| [NCT01553981](https://clinicaltrials.gov/study/NCT01553981) | Phase 3 | Completed | ILD Treatment Study |
| [NCT00430677](https://clinicaltrials.gov/study/NCT00430677) | Phase 2/3 | Terminated | Rheumatic Disease Study |
**Trial Summary**: 2 Phase 3 trials (1 completed), 2 Phase 4 trials, 4 Phase 2 trials
5. Leukemia, Lymphocytic, Susceptibility to L4 Hold
### Mengapa Ramalan Ini Munasabah
Basic research on corticosteroid effects on lymphocyte susceptibility. However, clinical evidence is limited.
### Ujian Klinikal
Only 1 N/A phase trial currently recruiting.
### Literatur
17 PubMed articles, primarily basic research and 2 case reports.
**Note**: More clinical evidence needed before proceeding.
Ringkasan Bukti
| Indication | Evidence Level | Trials | Articles | Recommendation |
|---|---|---|---|---|
| Lymphosarcoma | L1 | 50 | 20 | Go |
| Disease of Orbital Region | L1 | 50 | 20 | Go |
| Erythema Multiforme | L2 | 14 | 20 | Research Question |
| Rheumatic Heart Disease | L2 | 9 | 20 | Research Question |
| Leukemia, Lymphocytic | L4 | 1 | 17 | Hold |
Pendaftaran NPRA (Malaysia)
| Product | Registration No. | Holder | Status |
|---|---|---|---|
| Predsone Syrup 3mg/5ml | MAL06081197AZ | Pahang Pharmacy | Approved |
| Axcel Prednisolone-5mg Tablet | MAL21106027AZ | Kotra Pharma | Approved |
| Visolone Tablet 1mg | MAL16125034AZ | Y.S.P. Industries | Approved |
Total: 38 registered products
Sumber FHIR
Akses data ubat melalui API FHIR R4:
- MedicationKnowledge:
/fhir/MedicationKnowledge/DB00860
Sumber Berkaitan
| Sumber | Pautan |
|---|---|
| DrugBank | View on DrugBank |
| PubMed | Search PubMed |
| ClinicalTrials.gov | Search Trials |
Penafian
This report is for research purposes only and does not constitute medical advice. Drug repurposing decisions require complete clinical validation and regulatory review. Always consult healthcare professionals.
Last updated: 2026-03-04 | Analyzed by: Claude | MyTxGNN Research Team
This report is for research purposes only and does not constitute medical advice. Drug repurposing decisions require complete clinical validation and regulatory review. Always consult healthcare professionals.
Last updated: 2026-03-04 | Analyzed by: Claude | MyTxGNN Research Team